351 results on '"Schultheiss, Michael"'
Search Results
2. Product Organizations : How Successful Businesses Use Their Product Organization as a Competitive Advantage
3. Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency.
4. Produktorganisationen : Wie erfolgreiche Unternehmen ihre Produktorganisation als Wettbewerbsvorteil einsetzen
5. Evaluation of Laboratory and Sonographic Parameters for Detection of Portal Hypertension in Patients with Common Variable Immunodeficiency
6. The transjugular intrahepatic portosystemic shunt: Smaller stent diameters are required to optimize pressure response
7. WED-094 Food antigen-specific antibodies contribute to hypergammaglobulinemia in patients with decompensated liver cirrhosis
8. OS-112-YI Outcome and management of patients with hepatocellular carcinoma who achieved complete response to immunotherapybased systemic therapy
9. Die Leberzirrhose als Multisystemerkrankung
10. Aspirin improves transplant-free survival after TIPS implantation in patients with refractory ascites: a retrospective multicentre cohort study
11. Comparison of the Covered Self-Expandable Viatorr CX Stent with the Covered Balloon-Expandable BeGraft Peripheral Stent for Transjugular Intrahepatic Portosystemic Shunt (TIPS) Creation: a Single-Centre Retrospective Study in Patients with Variceal Bleeding
12. Fibrosis Progression in Patients with Budd–Chiari Syndrome and Transjugular Intrahepatic Portosystemic Shunt (TIPS): A Long-Term Study Using Transient Elastography
13. Fibrosis Progression in Patients with Budd-Chiari Syndrome and Transjugular Shunt (TIPS): A Long-Term Study Using Transient Elastography
14. Blood reelin in the progression of chronic liver disease
15. Percutaneous transcatheter aspiration of pulmonary embolism leading to diagnosis of hepatocellular carcinoma tumor embolus and change in systemic chemotherapy.
16. Komplikationen der Leberzirrhose.
17. Implantation of transjugular intrahepatic portosystemic shunt (TIPS): indication and patient selection
18. Komplikationen der Leberzirrhose
19. State of the art 2020: Transjugulärer intrahepatischer portosystemischer Shunt
20. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial
21. Proton pump inhibitor therapy is associated with reduced survival following first-time transarterial chemoembolization in patients with hepatocellular carcinoma
22. Ösophagusvarizen trotz TIPS!?
23. Prediction of postembolization syndrome after transarterial chemoembolization of hepatocellular carcinoma and its impact on prognosis
24. Decreased Platelet Aggregation in Patients with Decompensated Liver Cirrhosis and TIPS Implantation
25. Predictive Value of [99mTc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [90Y]-TARE: A Single-Center Experience
26. Adjuvant Transjugular Variceal Occlusion at Creation of a Transjugular Intrahepatic Portosystemic Shunt (TIPS): Efficacy and Risks of Bucrylate Embolization
27. Neue lokale und systemische Therapieoptionen beim HCC
28. Repeated SBRT for in- and out-of-field recurrences in the liver
29. Lopinavir serum concentrations of critically ill infants: a pharmacokinetic investigation in South Africa
30. Pressure response to TIPS does not depend on stent diameter
31. Serum procalcitonin and interleukin-6 predict acute-on-chronic liver failure following transjugular intrahepatic portosystemic shunt implantation in patients with refractory ascites
32. Correlation of lymphangiogenesis and inflammation in patients with ACLD
33. The transjugular intrahepatic portosystemic shunt (TIPS): Smaller stent diameters are required to prevent overtreatment.
34. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells
35. The role of albumin–bilirubin grade and inflammation-based index in patients with hepatocellular carcinoma treated with stereotactic body radiotherapy
36. Atezolizumab plus bevacizumab beyond first-line in hepatocellular carcinoma
37. Long-term PPI treatment is a risk factor for acute-on-chronic liver failure in patients with advanced cirrhosis: a propensity score matched analysis
38. Free Hepatic Vein Pressure Is Not Useful to Calculate the Portal Pressure Gradient in Cirrhosis: A Morphologic and Hemodynamic Study
39. Predictive Value of [ 99m Tc]-MAA-Based Dosimetry in Hepatocellular Carcinoma Patients Treated with [ 90 Y]-TARE: A Single-Center Experience.
40. Proton pump inhibitor treatment is associated with acute-on-chronic liver failure in patients with advanced cirrhosis.
41. Survival prediction using the Freiburg index of post-TIPS survival (FIPS) in critically ill patients with acute- on chronic liver failure: A retrospective observational study
42. Atezolizumab Plus Bevacizumab in Patients with Advanced and Progressing Hepatocellular Carcinoma: Retrospective Multicenter Experience
43. Hepatic decompensation after transarterial radioembolization: A retrospective analysis of risk factors and outcome in patients with hepatocellular carcinoma
44. T-cell exhaustion and residency dynamics inform clinical outcomes in hepatocellular carcinoma
45. Risk factors for short-term post discharge clinical outcomes in patients hospitalized with decompensated chronic liver disease: interim results from Global CLEARED study
46. CLEARED Global consortium results highlight regional variation and need for equity in inpatient outcomes in hospitalized patients with Chronic Liver Disease
47. Reduction of esophageal stent migration rate with a novel over-the-scope fixation device (with video)
48. The spatial distribution and detailed composition of infiltrating immune cells define autoimmune- and checkpoint-therapy associated hepatitis
49. Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis
50. IMMUNIB trial (AIO-HEP-0218/ass): A single-arm, phase II study evaluating safety and efficacy of immunotherapy nivolumab in combination with lenvatinib in advanced-stage hepatocellular carcinoma (HCC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.